Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Chemox: Transforming Healthcare Through Innovative Process.

## Sitemaps
[XML Sitemap](https://chemoxpharma.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Mirabegron API Manufacturer in India: Direct Factory Sourcing](https://chemoxpharma.com/mirabegron-api-manufacturer-in-india/): Mirabegron isn't an easy API to make well. Unlike simpler small molecules, its synthesis involves multiple stages of amine intermediate chemistry, heterocyclic ring formation, and chiral resolution  meaning the manufacturer behind your supply matters more here than it does for many other APIs. If you're searching for a Mirabegron API manufacturer in India, the difference between a company that actually runs this synthesis in-house and one reselling material sourced elsewhere shows up directly in your batch consistency and documentation depth.
- [Olmesartan Intermediate OLMI-1: Specifications & Sourcing](https://chemoxpharma.com/olmesartan-intermediate-olmi-1-specifications/): OLMI-1 sits right at the core of Olmesartan Medoxomil's molecular structure — it's the imidazole intermediate that everything else in the synthesis route gets built onto. If your process depends on this intermediate, its purity and consistency aren't just one input among many; they set the quality ceiling for every downstream step that follows. Understanding what Olmesartan Intermediate OLMI-1 actually is, and what to verify before you source it, matters more here than for almost any other intermediate in the chain.
- [Olmesartan Intermediate DMDO-CL: Specifications & Sourcing](https://chemoxpharma.com/olmesartan-intermediate-dmdo-cl/): This guide covers what Olmesartan Intermediate DMDO-CL actually is, its key specifications, where it fits in the synthesis route, and what to look for in a manufacturer before you order.
- [TTBB Manufacturer India: Direct Factory Sourcing Guide](https://chemoxpharma.com/ttbb-manufacturer-in-india/): If you manufacture Losartan, Valsartan, Irbesartan, Candesartan, or Olmesartan Medoxomil, TTBB (the trityl-protected tetrazole-biphenyl bromide) is almost certainly somewhere in your synthesis chain. It's one of the most widely used coupling intermediates across the entire sartan class  which also means it's one of the most commonly resold, relisted, and re-sourced intermediates on B2B chemical marketplaces. Finding a genuine TTBB manufacturer in India, rather than a trading company reselling someone else's output, directly affects your batch consistency, your documentation, and ultimately your finished API's yield.
- [Tadalafil API vs Sildenafil API: Comparing Usage Profiles for Formulators](https://chemoxpharma.com/tadalafil-api-vs-sildenafil-api/): This guide compares Tadalafil API vs Sildenafil API from a usage perspective  onset, duration, dosing pattern, and additional indications  so formulators can decide which fits their product roadmap.
- [Citicoline Sodium Injectable Grade vs Oral Grade: What’s the Difference?](https://chemoxpharma.com/citicoline-sodium-injectable-vs-oral-grade/): Not every batch of Citicoline Sodium API is built for the same dosage form. A buyer formulating an IV solution for acute stroke care has a very different specification requirement than one formulating a nootropic capsule for the supplement market — even though both start from the same base molecule. Understanding the difference between Citicoline Sodium injectable vs oral grade before you place an order prevents a mismatch that can hold up your formulation, your testing, or your regulatory submission.
- [Citicoline Sodium API Exporters India: What to Look For](https://chemoxpharma.com/citicoline-sodium-api-exporters-in-india/): If you've moved past researching manufacturers and are now specifically searching for a Citicoline Sodium API exporters India, you're likely closer to placing an order than a buyer still comparing general suppliers. But "manufacturer" and "exporter" aren't automatically the same thing  plenty of companies produce API well but have little to no real experience getting it through international logistics, documentation, and customs compliance. Choosing a company that hasn't done this often is where shipment delays and customs issues start.
- [Citicoline Sodium API Applications for Formulators](https://chemoxpharma.com/citicoline-sodium-api-applications-for-formulator/): This guide walks through citicoline sodium api applications & mechanism of action and its three major formulation categories  stroke recovery, traumatic brain injury (TBI), and cognitive health — along with what each application typically demands from the API itself.
- [Tadalafil API Manufacturer Certifications: WHO-GMP & ISO](https://chemoxpharma.com/tadalafil-api-manufacturer-certifications/): Understanding Tadalafil API manufacturer certifications  what each one actually covers, and how to verify a claim rather than just take it at face value  protects you from a costly mistake: building a formulation around an API that can't actually support your regulatory submission.
- [Citicoline Sodium API Manufacturer in India – Direct Factory Pricing, No Middlemen](https://chemoxpharma.com/citicoline-sodium-api-manufacturer-in-india/): If you're formulating a nootropic supplement, a stroke-recovery therapy, or a cognitive-health product, the supplier you choose for Citicoline Sodium API affects more than just your raw material cost. It affects your documentation, your batch consistency, and how much margin gets eaten up before the product even reaches your production line. Searching for a Citicoline Sodium API manufacturer in India is the right instinct  India remains one of the largest and most cost-competitive sources of this API globally — but not every listed "supplier" is actually the factory producing it.
- [Tadalafil API Manufacturer vs Trader: How to Tell the Difference](https://chemoxpharma.com/tadalafil-api-manufacturer-vs-trader/): Understanding Tadalafil API manufacturer vs trader distinctions before you commit to a supplier isn't just good practice — it directly affects your regulatory documentation, your pricing, your lead times, and how much control you have when something needs to be resolved quickly.
- [Tadalafil API with DMF Support: Manufacturer Guide 2026](https://chemoxpharma.com/tadalafil-api-with-dmf-support/): This guide covers exactly what Tadalafil API DMF support should look like from a real manufacturer, and what to check before you commit to a supplier for your next formulation project.
- [Citicoline Sodium API Export to Indonesia: BPOM Guide](https://chemoxpharma.com/citicoline-sodium-api-export-to-indonesia/): Indonesia is Southeast Asia's largest pharmaceutical market, and demand for neuroprotective and cognitive-health APIs like citicoline sodium has been climbing steadily alongside the country's growing focus on stroke care and brain-health nutraceuticals. But a citicoline sodium API export to Indonesia runs through one of ASEAN's more document-heavy regulatory systems — BPOM (Badan Pengawas Obat dan Makanan), Indonesia's National Agency of Drug and Food Control. If you're supplying formulators in Jakarta, Surabaya, or anywhere else in the archipelago, understanding BPOM's process before you quote a buyer will save months later.
- [Tadalafil API Export to Brazil: CADIFA & ANVISA Guide](https://chemoxpharma.com/tadalafil-api-export-to-brazil/): Brazil is one of the largest and fastest-growing pharmaceutical markets in Latin America, which makes it a natural target for any serious API supplier. But a tadalafil API export to Brazil isn't as simple as shipping a WHO-GMP certificate and a Certificate of Analysis. Brazil's regulator, ANVISA (Agência Nacional de Vigilância Sanitária), runs one of the most document-heavy API approval systems in the region  and if you don't understand the CADIFA process going in, you can lose months on preventable delays.
- [India pharma industry $120 billion Target : What It Means for API Exports](https://chemoxpharma.com/india-pharma-industry-120-billion-target/): India's Commerce and Industry Minister Piyush Goyal said the India pharma industry $120 billion target is well within reach the sector, currently valued at approximately $60 billion, has the potential to double within the next five years
- [High Potency API Manufacturing: Containment & Sourcing Guide](https://chemoxpharma.com/high-potency-api-manufacturing/): High Potency API Manufacturing (HPAPIs) are compounds that are pharmacologically active at extremely low doses  often micrograms or even nanograms  meaning that even trace-level occupational exposure during manufacturing can pose a genuine health risk to production staff. This single characteristic changes everything about how these molecules must be developed, manufactured, handled, and sourced.
- [Oncology API Market Growth 2026: The Fastest-Growing Category](https://chemoxpharma.com/oncology-api-market-growth-2026/): Of every therapeutic category tracked in the global API manufacturing market, one is consistently singled out by market analysts as the standout oncology API market growth 2026 : oncology.
- [US Pharma Tariffs 2026 India: What API Buyers Need to Know](https://chemoxpharma.com/us-pharma-tariffs-2026-india/): On April 2, 2026, President Trump signed a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing a 100% tariff on imported patented pharmaceutical products and their associated active pharmaceutical ingredients. It is one of the most significant US trade actions to hit the pharmaceutical sector in decades  and it has understandably triggered concern among pharma buyers and Indian API exporters alike.
- [AI Pharmaceutical Quality Control 2026 :What’s Changing](https://chemoxpharma.com/ai-pharmaceutical-quality-control-2026-whats-changing/): For procurement teams and quality professionals evaluating API manufacturers, this raises a genuinely practical question: what does AI pharmaceutical quality control actually mean on a production floor in 2026, what has regulatory backing, what is still emerging, and what should you actually be asking your API supplier about their quality systems?
- [API Manufacturer vs Trader vs Broker: Key Differences](https://chemoxpharma.com/api-manufacturer-vs-trader-difference/): This distinction  API manufacturer vs trader is one of the most consequential and least understood factors in pharmaceutical procurement. It rarely shows up clearly on a company's website. It's almost never asked about directly in an initial inquiry. And it is very often the single biggest factor separating a reliable, auditable, regulation-ready supply chain from one that is one bad batch away from a serious quality incident.
- [Biosimilars vs Biologics API: What Every Buyer Must Know](https://chemoxpharma.com/biosimilars-vs-biologics-api/): If you are a pharmaceutical procurement professional, regulatory affairs manager, or formulation scientist navigating the global API sourcing landscape in 2026, there is one fundamental distinction you must understand clearly: biosimilars vs biologics API what makes them different, why those differences matter enormously for manufacturing, regulatory strategy, and sourcing decisions, and why the explosive growth of the biosimilars market is creating one of the most significant API sourcing opportunities of the decade.
- [Erectile Dysfunction Drug Market 2026: Generic Sildenafil API](https://chemoxpharma.com/erectile-dysfunction-drug-market-2026/): The erectile dysfunction drug market 2026 is at a pivotal inflection point. A condition once spoken about only in whispers is now the subject of multi-billion-dollar pharmaceutical investment, telemedicine disruption, and one of the most compelling generic API sourcing opportunities in the global pharmaceutical industry. With over 320 million men worldwide affected by erectile dysfunction  and more than 50% of men aged between 40 and 70 reporting some form of the condition  the demand for effective, affordable ED treatment is structural, growing, and global.
- [Tadalafil API Price Per Kg in 2026: Cost Factors & Buyer Guide](https://chemoxpharma.com/tadalafil-api-price-per-kg/): Tadalafil API price per kg is one of the most searched procurement queries in the PDE5 inhibitor space. And with good reason: the market has changed substantially since Eli Lilly's Cialis patent expired in late 2023. The entry of dozens of new generic manufacturers globally has increased supply, intensified competition, and pushed prices into new territory — but the range remains wide depending on grade, volume, supplier type, and regulatory documentation requirements.
- [Generic Drug Market 2026: Size, Growth & India’s Role](https://chemoxpharma.com/generic-drug-market-2026/): The generic drug market 2026 is one of the most consequential stories in global healthcare a nearly half-trillion-dollar industry that keeps medicines affordable for billions of patients worldwide, sustains the economics of national healthcare systems, and creates the largest single demand driver for Active Pharmaceutical Ingredients manufactured in India. Understanding its size, its growth trajectory, and the forces shaping it is essential intelligence for every pharmaceutical manufacturer, API supplier, procurement professional, and investor operating in the global pharma supply chain.
- [Pharmaceutical API Market 2026: Global Trends & Forecast](https://chemoxpharma.com/pharmaceutical-api-market-2026/): The pharmaceutical API market 2026 represents one of the most significant investment and sourcing opportunities in the entire global healthcare industry. As the backbone of every medicine produced worldwide  from a paracetamol tablet to a complex monoclonal antibody the active pharmaceutical ingredient market underpins a USD 1.5 trillion global pharmaceutical industry that shows no signs of slowing.
- [What Is a Certificate of Analysis (CoA) in Pharma? A Guide for API Buyers](https://chemoxpharma.com/what-is-certificate-of-analysis-in-pharma/): Every kilogram of Active Pharmaceutical Ingredient that crosses an international border carries with it a document that can make or break a regulatory submission, a shipment clearance, or a patient's safety: the Certificate of Analysis. Yet despite its critical importance, many pharmaceutical procurement teams  particularly those new to sourcing APIs from India or other international manufacturers  do not fully understand what a certificate of analysis in pharma document must contain, how to read it correctly, or how to identify a fraudulent or non-compliant one before it causes serious problems.
- [India vs China API Supply: Why Global Buyers Are Diversifying in 2026](https://chemoxpharma.com/india-vs-china-api-supply/): In 2026, the global India vs China API supply conversation has shifted from academic discussion to urgent procurement strategy. Pharmaceutical companies across MENA, Europe, Africa, and the Americas are actively qualifying Indian API manufacturers as primary or secondary sources  not as a backup plan, but as a deliberate structural decision to build supply chains that are more resilient, better documented, and less exposed to a single geography's political and logistical risk.
- [CDMO vs API Manufacturer: What’s the Difference and Which Do You Need?](https://chemoxpharma.com/cdmo-vs-api-manufacturer/): If you're looking for active pharmaceutical ingredients or starting a new drug, you might know the terms CDMO and API manufacturer. While they often seem similar, they actually mean different things.
- [Tadalafil API Manufacturer India: WHO-GMP Certified, IP/BP/USP Grades Available](https://chemoxpharma.com/tadalafil-api-manufacturer-india/): Global demand for Tadalafil API has never been stronger. As the generic pharma market expands across MENA, Africa, Southeast Asia, and Europe, pharmaceutical companies worldwide are actively searching for a reliable tadalafil API manufacturer in India — one that can supply consistently pure, multi-pharmacopoeia compliant material, backed by complete regulatory documentation and an auditable GMP facility.
- [Antihistamine API Supplier India: OTC & Rx Market Guide](https://chemoxpharma.com/antihistamine-api-supplier-india/): Allergies are among the most widespread chronic conditions on the planet — and the medicines that manage them are among the most consistently purchased pharmaceutical products in the world. Behind every Cetirizine tablet dispensed at a retail pharmacy in Lagos, every Fexofenadine capsule sold over the counter in Dubai, and every Loratadine syrup prescribed at a clinic in Jakarta, is an active pharmaceutical ingredient that almost certainly originated from an antihistamine API supplier India operates.
- [Antibiotic API Manufacturer India: Market 2026–2036 Guide](https://chemoxpharma.com/antibiotic-api-manufacturer-india-market-2026/): When a patient in Cairo receives a course of Azithromycin, or a hospital in Nairobi dispenses Amoxicillin, or a pharmacy in Lagos stocks Cephalexin the active ingredient powering that medicine almost certainly originated in India. This is not coincidence. It is the result of decades of deliberate investment, regulatory excellence, and manufacturing scale that has made every leading antibiotic API manufacturer India operates a cornerstone of the global pharmaceutical supply chain.
- [Top 5 APIs Demand Across Middle East and Africa API market](https://chemoxpharma.com/top-5-api-middle-east-and-africa-api-market/): The Middle East and Africa pharmaceutical market is one of the most dynamic growth stories in global healthcare. The Middle East and Africa API market was valued at USD 7.78 billion in 2024 and is expected to reach USD 12.69 billion by 2032, growing at a CAGR of 6.3%. Driving this growth is a powerful combination of rapidly expanding populations, rising chronic disease burdens, expanding universal healthcare coverage, and aggressive government investment in local pharmaceutical manufacturing infrastructure.
- [Cardiovascular API Supplier India: Backbone of MENA Pharma](https://chemoxpharma.com/cardiovascular-api-supplier-india-mena-pharma/): Heart disease does not pause for geography. Across the Middle East and North Africa, cardiovascular disease (CVD) is the single largest cause of death  and the pharmaceutical supply chain keeping millions of patients alive runs, in large part, through India. Every cardiovascular API supplier India exports to the MENA region is playing a critical, life-sustaining role in one of the world's fastest-growing pharmaceutical markets.
- [How to Qualify API Supplier India: A Step-by-Step Guide](https://chemoxpharma.com/how-to-qualify-api-supplier-india-a-step-by-step-guide/): This is why knowing how to qualify API supplier India is one of the most critical competencies a global pharmaceutical procurement or regulatory affairs team can develop. India is the world's largest supplier of generic APIs, exporting to over 191 countries and holding more USFDA-approved manufacturing facilities than any country outside the United States. But not every Indian API manufacturer is equal  and a structured, rigorous qualification process is the only reliable way to separate the best from the rest.
- [Overcoming Particle Size Distribution Mismatches in Tech Transfer](https://chemoxpharma.com/particle-size-distribution-mismatches-tech-transfer/): The root cause of these unexpected failures is rarely chemical; it is physical. Specifically, it stems from unaddressed particle size distribution mismatches between the R&D clinical batches and the commercial scale-up operations. Understanding the underlying physical chemistry of physical attributes is vital to ensuring a seamless, right-first-time technology transfer.
- [Why Egypt Is a Strategic Hub for Pharmaceutical API Imports from India](https://chemoxpharma.com/api-import-india-to-egypt-pharma/): API import India to Egypt pharma relationships are deepening at an accelerating pace in 2026, driven by Egypt's booming pharmaceutical market, a growing burden of chronic disease, ambitious government localization policies, and India's unmatched ability to supply compliant, cost-effective APIs at scale. In this blog, we explore the forces reshaping this bilateral pharmaceutical relationship and why Indian API suppliers are best positioned to benefit.
- [Indian API GMP Certification Export: USFDA vs WHO vs EU](https://chemoxpharma.com/indian-api-gmp-certification-export/): Understanding Indian API GMP certification export standards is not a box-ticking exercise. It directly determines whether your finished drug product will pass regulatory scrutiny in the United States, Europe, or emerging markets or get flagged at the border. India holds over 600 USFDA-approved pharmaceutical facilities outside the US, and more than 1,400 WHO-GMP certified sites  the highest concentration of internationally certified API manufacturing infrastructure in the world. Yet not all certifications are equal, and not all markets accept the same credentials.
- [Top Challenges in API export regulatory compliance India 2026](https://chemoxpharma.com/api-export-regulatory-compliance-india-2026/): India is rightfully called the Pharmacy of the World. With pharmaceutical exports crossing USD 30.5 billion in 2024–25 and APIs shipped to over 191 countries, Indian manufacturers have cemented their place as the backbone of the global generic drug supply chain. The India API market, valued at USD 14.18 billion in 2025, is forecast to reach USD 22.18 billion by 2031 — a clear signal that global demand is only accelerating.
- [Why Indian Manufacturers Are the Top Mirabegron API Suppliers for Global Pharma](https://chemoxpharma.com/mirabegron-api-supplier-india-pharma/): The global demand for Mirabegron the gold-standard active pharmaceutical ingredient (API) for treating overactive bladder (OAB) — is surging. As pharmaceutical companies across the United States, Europe, and emerging markets race to formulate high-quality generic versions of this vital drug, one question consistently rises to the top of procurement discussions: Where is the most reliable, compliant, and cost-effective Mirabegron API supplier?
- [Why Chemox Pharma Is the Top Rosuvastatin API Manufacturer in India](https://chemoxpharma.com/top-rosuvastatin-api-manufacturer-in-india/): In today's highly competitive pharmaceutical landscape, finding a reliable and high-quality Rosuvastatin API manufacturer in India is critical for formulators, branded drug companies, and generic manufacturers worldwide. Rosuvastatin — the active pharmaceutical ingredient (API) at the heart of cholesterol-lowering medications — demands precision chemistry, stringent quality control, and consistent supply chain reliability.
- [Nitrofurantoin API: UTI Treatment & Manufacturing Excellence](https://chemoxpharma.com/nitrofurantoin-api-uti-treatment-manufacturing/): Introduction Urinary Tract Infections (UTIs) represent a significant global health challenge, affecting millions annually. In the ongoing battle against these common bacterial infections, Nitrofurantoin Active Pharmaceutical Ingredient (API) stands as a foundational and highly effective treatment. Its enduring efficacy and favorable resistance profile make it a critical component in the pharmaceutical arsenal against UTIs. This article delves into the therapeutic importance of Nitrofurantoin API, the stringent manufacturing controls essential for producing a high-purity and effective API, and highlights Chemox Pharma's expertise in antibacterial API production. The Therapeutic Importance of Nitrofurantoin in UTI Treatment Nitrofurantoin, a synthetic nitrofuran derivative, has been a cornerstone in UTI treatment since its introduction in 1953 . Its unique mechanism of action sets it apart from many other antibiotics. Instead of targeting a single bacterial pathway, Nitrofurantoin works by inhibiting multiple bacterial enzyme systems, including those involved in DNA and RNA synthesis, protein synthesis, and aerobic energy metabolism . This multi-targeted approach contributes to its sustained efficacy and a lower propensity for resistance development compared to other classes of antibiotics, such as fluoroquinolones or sulfonamide. Crucially, Nitrofurantoin is concentrated in the urine, making it exceptionally effective for treating uncomplicated lower UTIs. This localized action minimizes systemic exposure and potential side effects, further solidifying its role as a first-line treatment option. The World Health Organization (WHO) recognizes Nitrofurantoin as an essential medicine, underscoring its critical role in global public health . Manufacturing Excellence: Ensuring High-Purity Nitrofurantoin API The effectiveness and safety of any pharmaceutical product are directly linked to the quality of its active pharmaceutical ingredient. For Nitrofurantoin API, stringent manufacturing controls are paramount to ensure high purity, consistent quality, and optimal therapeutic performance. Manufacturers must adhere to global regulatory standards, including WHO-GMP (Good Manufacturing Practices), and comply with pharmacopoeial requirements such as IP (Indian Pharmacopoeia), BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopoeia) . Key considerations in Nitrofurantoin API manufacturing include: Purity Standards: Achieving and maintaining a high purity level, typically exceeding 99%, is crucial to minimize impurities that could affect drug safety and efficacy. Particle Size Distribution (PSD): Nitrofurantoin is often available in different physical forms, each with specific particle size characteristics that influence its dissolution rate, bioavailability, and gastrointestinal tolerance. These forms include: Nitrofurantoin Anhydrous: Ideal for standard tablet and capsule formulations. Nitrofurantoin Monohydrate: Often used in combination with macrocrystals for sustained-release formulations, offering smaller particle sizes and higher solubility for rapid dissolution . Nitrofurantoin Macrocrystals: Specifically engineered with larger particles for better gastrointestinal tolerance and controlled absorption, reducing common side effects like nausea . Precise control over the crystallization process and subsequent particle size reduction techniques are vital to produce these distinct forms, ensuring they meet the specific needs of various pharmaceutical formulations. Chemox Pharma's Expertise in Antibacterial API Production As a leading Nitrofurantoin API manufacturer, Chemox Pharma is committed to delivering high-quality, compliant ingredients to the global pharmaceutical industry. Our state-of-the-art manufacturing facility in Dahej, Gujarat, operates under strict WHO-GMP guidelines, employing advanced technology and rigorous quality control measures at every stage of production . Chemox Pharma's commitment to excellence is demonstrated through: WHO-GMP Certified Production: Our adherence to global GMP standards ensures that every batch of Nitrofurantoin API is produced under controlled conditions, guaranteeing consistent quality and purity. Comprehensive Regulatory Support: We provide extensive support for regulatory submissions, including Drug Master File (DMF) filings and complete documentation for IP, BP, EP, and USP grades. This streamlines the approval process for our partners' finished dosage forms in diverse international markets . Diverse Product Forms: Understanding the varied formulation needs, Chemox Pharma offers Nitrofurantoin in its Anhydrous, Monohydrate, and Macrocrystalline forms, providing flexibility and tailored solutions for different drug delivery systems. Strategic Location and Supply Chain: Situated in India's pharmaceutical hub, Chemox Pharma benefits from robust logistics and a well-established supply chain, enabling competitive pricing and timely delivery to over 90 countries worldwide . Our scientific expertise, combined with decades of experience in antibacterial API production, positions Chemox Pharma as a trusted partner for pharmaceutical formulators and procurement teams seeking reliable and high-purity Nitrofurantoin API. Conclusion Nitrofurantoin API remains an indispensable treatment for urinary tract infections, valued for its efficacy and low resistance profile. The successful formulation of Nitrofurantoin-based drugs hinges on the quality and purity of the API, necessitating stringent manufacturing controls and adherence to global regulatory standards. Chemox Pharma stands at the forefront of this critical field, offering high-purity Nitrofurantoin API backed by WHO-GMP certified production, comprehensive regulatory support, and a commitment to manufacturing excellence. Partnering with a reputable manufacturer like Chemox Pharma ensures the integrity and effectiveness of UTI treatments, ultimately benefiting patients worldwide.
- [Mirabegron API: Innovations in Overactive Bladder Treatment](https://chemoxpharma.com/mirabegron-api-innovations-in-overactive-bladder-treatment/): Introduction Overactive Bladder (OAB) is a chronic condition characterized by a sudden, uncontrollable urge to urinate, often leading to urinary incontinence, increased urinary frequency, and nocturia. It significantly impacts the quality of life for millions worldwide. While various treatments exist, Mirabegron, a beta-3 adrenergic receptor agonist, has emerged as a significant advancement in OAB therapy. This blog post delves into the innovations surrounding Mirabegron API, its role in modern OAB treatment, and the stringent manufacturing standards that ensure its efficacy and safety. Mirabegron: A New Era in OAB Treatment Mirabegron offers a distinct mechanism of action compared to traditional anticholinergic medications. Instead of blocking muscarinic receptors, Mirabegron selectively activates beta-3 adrenergic receptors in the bladder detrusor muscle. This activation leads to relaxation of the bladder smooth muscle during the storage phase of the micturition cycle, increasing bladder capacity without inhibiting bladder contraction during voiding . This novel approach often results in a more favorable side effect profile, particularly regarding dry mouth and constipation, which are common with anticholinergics, thereby improving patient adherence and overall treatment outcomes. Innovations in Mirabegron API Manufacturing The production of Mirabegron API demands rigorous adherence to pharmaceutical manufacturing standards to ensure purity, potency, and consistency. Innovations in this area focus on several key aspects: 1. Quality by Design (QbD) Approach Many leading API manufacturers employ a Quality by Design (QbD) approach for Mirabegron API synthesis. QbD integrates scientific understanding and risk management into the development and manufacturing process, ensuring that the final product consistently meets predefined quality attributes. This includes identifying critical material attributes (CMAs) and critical process parameters (CPPs) that influence API quality, leading to robust and efficient manufacturing processes . 2. Advanced Synthesis Routes Research and development efforts are continuously exploring more efficient, cost-effective, and environmentally friendly synthesis routes for Mirabegron API. Innovations include: Concise Synthesis of Key Intermediates: Development of scalable synthesis methods for key intermediates, often employing greener reagents and avoiding expensive or toxic condensation agents . Novel Catalytic Processes: Exploration of new catalytic systems that enhance reaction selectivity and yield, reducing the formation of impurities. Chiral Purity Control: Mirabegron has a specific stereochemistry crucial for its pharmacological activity. Advanced manufacturing processes focus on controlling chiral purity to ensure the desired enantiomer is produced with high specificity, minimizing the presence of inactive or potentially harmful isomers . 3. Impurity Profiling and Control Stringent impurity profiling and control are paramount for Mirabegron API. Manufacturers utilize advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry, to identify and quantify potential impurities, including process-related impurities, degradation products, and residual solvents. This comprehensive profiling ensures compliance with international regulatory guidelines, such as those from the ICH (International Council for Harmonisation) . 4. Regulatory Compliance and Global Standards Mirabegron API production must comply with global regulatory standards, including European Pharmacopoeia (EP), United States Pharmacopeia (USP), and current Good Manufacturing Practices (cGMP). Facilities undergo regular inspections by international regulatory authorities to ensure adherence to these stringent quality and safety standards . The Growing Market for Mirabegron API The global market for Mirabegron API is experiencing significant growth, driven by the increasing prevalence of OAB, an aging global population, and the drug's favorable efficacy and safety profile. Projections indicate a substantial increase in market size over the coming years, making it a crucial segment for pharmaceutical contract development and manufacturing organizations (CDMOs) . Conclusion Mirabegron API represents a significant leap forward in the treatment of overactive bladder, offering patients an effective and well-tolerated therapeutic option. The continuous innovations in its manufacturing processes, driven by a commitment to Quality by Design, advanced synthesis routes, stringent impurity control, and adherence to global regulatory standards, underscore the pharmaceutical industry's dedication to delivering high-quality and safe medications. As the demand for effective OAB treatments grows, the focus on Mirabegron API will undoubtedly continue to drive further advancements in both its production and therapeutic application.
- [DMF Filing Process: US & EU API Regulatory Markets](https://chemoxpharma.com/dmf-filing-process-us-eu-regulatory-guide/): A Comprehensive Guide to Drug Master File (DMF) Submissions for the US and EU Markets In the highly regulated world of pharmaceutical manufacturing, securing API regulatory approvals is a critical milestone for any manufacturer aiming to supply global markets. The primary mechanism for providing confidential information about the manufacturing, processing, and quality of an Active Pharmaceutical Ingredient (API) is the Drug Master File (DMF). However, the DMF filing process varies significantly between the United States and the European Union. Navigating these complexities requires a deep understanding of both FDA and EMA requirements, as well as the specialized CEP certification process in Europe. As a leading pharmaceutical API manufacturer, Chemox Pharma prioritizes transparency and compliance. This guide provides a structured overview of the submission pathways for the US and EU markets, helping you streamline your regulatory strategy for 2026 and beyond. 1. The US Market: FDA Drug Master Files (DMF) In the United States, the Food and Drug Administration (FDA) manages the DMF system. A DMF filing process is a voluntary submission that allows a manufacturer to provide proprietary information directly to the FDA, which can then be referenced by an applicant (such as a drug product manufacturer) without disclosing trade secrets to that applicant . Types of US DMFs The FDA categorizes DMFs into several types, but for API manufacturers, Type II is the most relevant: Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product. Type III: Packaging Material. Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation. The FDA Submission Process The DMF filing process in the US has transitioned entirely to the Electronic Common Technical Document (eCTD) format. Key steps include: Requesting a Pre-Assigned Number: Before submission, manufacturers must obtain a unique DMF number from the FDA. eCTD Formatting: The dossier must be structured according to Module 1 through Module 5 of the eCTD hierarchy. GDUFA Fees: For DMFs referenced in Abbreviated New Drug Applications (ANDAs), manufacturers must pay a one-time fee under the Generic Drug User Fee Amendments (GDUFA) . Completeness Assessment: The FDA performs a technical review to ensure the DMF contains all necessary information before it can be officially referenced. 2. The European Market: ASMF and CEP The European Union offers two primary routes for API regulatory compliance: the Active Substance Master File (ASMF) and the Certificate of Suitability (CEP). Active Substance Master File (ASMF) The ASMF procedure (formerly known as the European DMF) is used when an API is not described in the European Pharmacopoeia (Ph. Eur.). Like the US DMF, it consists of two parts : Applicant’s Part (Open Part): Contains non-confidential information shared with the drug product manufacturer. Restricted Part (Closed Part): Contains confidential manufacturing details submitted only to the regulatory authorities (EMA or National Competent Authorities). CEP Certification (EDQM) The CEP certification, issued by the European Directorate for the Quality of Medicines & Healthcare (EDQM), is often the preferred route for APIs listed in the Ph. Eur. A CEP demonstrates that the API’s quality is adequately controlled by the monograph of the European Pharmacopoeia . Advantages of the CEP Route: Multi-Market Acceptance: A CEP is recognized by all 39 member states of the European Pharmacopoeia Convention and many other countries globally. Simplified Applications: Drug product manufacturers can simply include a copy of the CEP in their Marketing Authorization Application (MAA) instead of a full ASMF. Standardized Review: The EDQM centralizes the review process, ensuring consistency across the region. 3. Key Differences: US DMF vs. EU ASMF vs. CEP Understanding the nuances between these pathways is essential for a successful global launch. Feature US FDA DMF (Type II) EU ASMF EU CEP (EDQM) Applicability Any API (Novel or Generic) APIs not in Ph. Eur. APIs listed in Ph. Eur. Confidentiality Fully protected from applicant Protected via Restricted Part Protected via EDQM review Review Trigger Triggered by an IND/NDA/ANDA Triggered by an MAA Centralized review by EDQM Global Reach USA only EU & EEA countries EU + 39+ countries globally Format Mandatory eCTD eCTD or NeeS eCTD preferred 4. Best Practices for a Successful Submission To ensure a smooth DMF filing process and avoid costly Refuse-to-File (RTF) actions, manufacturers should: Maintain GMP Compliance: Both the FDA and EDQM conduct risk-based inspections of manufacturing sites. Ensure your facility, such as our unit in Dahej, adheres to the latest WHO-GMP standards . Ensure Data Integrity: Rigorous validation of analytical methods and stability data is non-negotiable. Regular Maintenance: DMFs and ASMFs must be updated annually or whenever significant changes occur in the manufacturing process. Conclusion Securing API regulatory approvals through DMF and CEP submissions is a complex but rewarding endeavor. By choosing the right pathway—whether it's the eCTD route for the US FDA or the centralized CEP route for Europe—manufacturers can significantly accelerate their time-to-market. At Chemox Pharma, we pride ourselves on our robust regulatory support and our ability to provide high-quality, compliant APIs to partners worldwide.
- [Citicoline Sodium vs. Alpha-GPC: Get the Right API for Cognitive Formulations](https://chemoxpharma.com/citicoline-sodium-vs-alpha-gpc-cognitive-health-api/): The burgeoning market for cognitive health supplements, often referred to as nootropics, has driven significant innovation in pharmaceutical formulations. At the heart of many effective brain health products are active pharmaceutical ingredients (APIs) like Citicoline Sodium and Alpha-GPC. Both are renowned for their ability to support cognitive function, yet they possess distinct mechanisms of action, bioavailability profiles, and ideal applications. For formulators and manufacturers, understanding these differences is crucial for selecting the optimal API to achieve desired product outcomes. This comprehensive guide will delve into the scientific distinctions between Citicoline Sodium and Alpha-GPC, providing the insights necessary to make informed decisions for your next cognitive health formulation. As a leading pharmaceutical API manufacturer, Chemox Pharma is committed to supplying high-quality ingredients that meet the stringent demands of the global market. Understanding Citicoline Sodium Citicoline, also known as CDP-Choline, is a naturally occurring compound that plays a vital role in the synthesis of phosphatidylcholine, a major component of neuronal cell membranes. It comprises two essential molecules: cytidine and choline. This dual-action structure allows Citicoline Sodium to offer broad neuroprotective and cognitive-enhancing benefits. Mechanism of Action: Citicoline Sodium works by : Choline Donation: It provides choline, a precursor to acetylcholine, a neurotransmitter critical for memory, learning, and attention. Phospholipid Synthesis: The cytidine component is converted into uridine, which, along with choline, aids in the repair and regeneration of neuronal membranes. This process is crucial for maintaining the structural integrity and fluidity of brain cells. Energy Metabolism: Citicoline supports mitochondrial function and ATP production in the brain, enhancing overall brain energy metabolism. Neuroprotection: It exhibits neuroprotective effects by reducing oxidative stress and inflammation, particularly after neurological events like stroke or traumatic brain injury. Key Benefits and Applications: Formulations containing Citicoline Sodium are often targeted for : Long-term Brain Health: Its role in membrane repair makes it ideal for sustained cognitive support and neuroprotection. Stroke Recovery: Clinical studies have shown its efficacy in improving outcomes and reducing cognitive deficits post-stroke. Age-Related Cognitive Decline: It helps in slowing the progression of memory impairment associated with aging and neurodegenerative conditions. Enhanced Focus and Memory: In healthy individuals, it can improve attention, concentration, and verbal memory. Exploring Alpha-GPC Alpha-GPC (L-Alpha-glycerylphosphorylcholine) is another potent choline compound, recognized for its rapid and efficient delivery of choline to the brain. Unlike Citicoline, Alpha-GPC is a phospholipid metabolite found naturally in the brain and is considered a direct precursor to acetylcholine. Mechanism of Action: Alpha-GPC primarily functions by : Direct Choline Delivery: It readily crosses the blood-brain barrier and is quickly converted into free choline, which is then used to synthesize acetylcholine. This direct pathway leads to a rapid increase in acetylcholine levels. Growth Hormone Release: Some research suggests Alpha-GPC may stimulate the release of growth hormone, which can have anabolic effects and support cellular repair. Key Benefits and Applications: Alpha-GPC is frequently chosen for formulations aimed at : Acute Cognitive Boost: Its rapid action makes it suitable for products designed for immediate improvements in focus, alertness, and mental performance. Athletic Performance: Due to its potential role in growth hormone release and muscle function, it's popular in sports nutrition for enhancing power output and recovery. Memory Enhancement: By increasing acetylcholine, it can significantly improve memory recall and learning capacity. Citicoline Sodium vs. Alpha-GPC: A Comparative Analysis While both APIs are excellent sources of choline for brain health, their differences dictate their optimal use in various formulations. The table below summarizes their key distinctions: Feature Citicoline Sodium Alpha-GPC Chemical Structure Cytidine Diphosphate-Choline L-Alpha-glycerylphosphorylcholine Primary Mechanism Choline donor & Phospholipid precursor Direct choline donor Bioavailability Moderate (requires metabolic conversion) High (direct conversion to choline) Onset of Action Gradual, sustained effects Rapid, acute effects Main Benefits Neuroprotection, membrane repair, long-term cognitive support Acute cognitive boost, memory, athletic performance Ideal Applications Chronic cognitive conditions, stroke recovery, daily brain health Nootropic stacks for immediate focus, sports supplements Cost Generally more cost-effective for broad applications Often higher due to direct action and purity Verdict: For formulations requiring comprehensive neuroprotection and sustained cognitive benefits, Citicoline Sodium is often preferred. For products aiming for a rapid, acute cognitive enhancement or sports performance, Alpha-GPC may be the API of choice. However, it's worth noting that some studies suggest a potential cardiovascular risk signal with Alpha-GPC that Citicoline avoids . The Chemox Pharma Advantage in API Manufacturing Choosing the right API is only the first step; ensuring its quality, purity, and consistent supply is paramount. At Chemox Pharma, we specialize in manufacturing high-quality Active Pharmaceutical Ingredients, including Citicoline Sodium API, adhering to the strictest global standards. Our state-of-the-art facility in Dahej, India, is WHO-GMP certified, ensuring that every batch of API meets international regulatory requirements. We provide comprehensive documentation, including batch-specific Certificates of Analysis (COA) and stability data, giving our partners complete confidence in their formulations. Our commitment to innovation and quality makes us the preferred pharmaceutical API manufacturer for leading brands worldwide. Conclusion Both Citicoline Sodium and Alpha-GPC offer significant benefits for cognitive health formulations, each with its unique strengths. By carefully considering their mechanisms, benefits, and applications, formulators can select the API that best aligns with their product's goals. When partnering with Chemox Pharma, you gain access to not only premium-quality APIs for nootropics but also a reliable and compliant manufacturing partner dedicated to your success in the dynamic cognitive health market.
- [India vs China: Who Dominates Montelukast Sodium API Manufacturing in 2026?](https://chemoxpharma.com/montelukast-sodium-api-manufacturer-india-vs-china-2026/): India has emerged as the world's most trusted source for Montelukast Sodium API Manufacturer and for good reason. Indian manufacturers hold an unmatched combination of global regulatory approvals, export experience, and R&D capability.
- [Why Choose Chemox Pharma as Your Montelukast Sodium API Supplier?](https://chemoxpharma.com/montelukast-sodium-api-supplier-chemox-pharma/): On the risk side, intense supplier competition has created price volatility and quality inconsistency. The influx of high-capacity but lower-compliance manufacturers  particularly in some parts of Asia — has led to batch-to-batch variability, impurity profile deviations, and delayed deliveries that disrupt formulation timelines for pharmaceutical companies. As a result, the most sophisticated pharma buyers in 2026 are not simply searching for the cheapest Montelukast Sodium API Supplier they are searching for the most dependable one.
- [How Impurity Profiling in API Manufacturing Affects Drug Safety](https://chemoxpharma.com/impurity-profiling-api-manufacturing-drug-safety/): When a patient takes a tablet or capsule, they trust that the medicine contains exactly what it is supposed to — nothing more, nothing less. But behind that trust lies one of the most technically demanding processes in pharmaceutical manufacturing: impurity profiling in API manufacturing.
- [Top Therapeutic Areas Driving API Demand in 2026](https://chemoxpharma.com/top-therapeutic-areas-driving-api-demand-in-2026/): In this article, we break down the four key therapeutic areas driving API demand in 2026: cardiovascular, oncology, central nervous system (CNS), and anti-infectives.
- [How to Choose a Reliable Montelukast Sodium API Manufacturer in India](https://chemoxpharma.com/best-montelukast-sodium-api-manufacturer-india/): The global demand for high-quality respiratory treatments has placed Montelukast Sodium at the forefront of the pharmaceutical supply chain. As a selective leukotriene receptor antagonist, it is indispensable for managing asthma and allergic rhinitis. However, for pharmaceutical formulators, the success of the final dosage form depends entirely on the quality of the Active Pharmaceutical Ingredient (API). India has emerged as the global hub for API manufacturing, offering a blend of cost-efficiency and world-class quality. But with numerous players in the market, how do you identify a truly reliable partner? This guide outlines the critical factors to consider when choosing a Montelukast Sodium API manufacturer in India. Understanding the Strategic Importance of Montelukast Sodium Montelukast Sodium (CAS No. 151767-02-1) is the primary ingredient in medications used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma. It is also used to prevent bronchospasm during exercise and treat symptoms of seasonal or perennial allergic rhinitis. Because these conditions are chronic, patients require consistent, long-term medication. This places an immense responsibility on the API manufacturer to ensure every batch meets stringent purity and stability standards. Key Factors to Evaluate in an Montelukast Sodium API Manufacturer When vetting potential suppliers, a "one-size-fits-all" approach does not work. You need to look for specific indicators of reliability and technical competence. 1. Regulatory Compliance and Certifications The most reliable manufacturers operate out of GMP-certified facilities. Regulatory compliance is the bedrock of pharmaceutical safety. Ensure the manufacturer holds: WHO-GMP Certification: Ensures the facility adheres to international manufacturing standards. ISO Certifications: Demonstrates a commitment to quality management systems. DMF (Drug Master File) Availability: A comprehensive DMF is essential for regulatory submissions in global markets like the US and Europe. CEP (Certificate of Suitability): Confirms that the API meets the requirements of the European Pharmacopoeia. 2. Quality Assurance and Purity Levels The efficacy of Montelukast Sodium is highly sensitive to impurities. Top-tier manufacturers in India, such as Chemox Pharma, utilize advanced chromatography and analytical techniques to achieve purity levels of 99% or higher. Ask for a detailed Certificate of Analysis (CoA) for recent batches to verify: Impurity profiles. Particle size distribution (critical for formulation stability). Residual solvent levels. 3. Manufacturing Capacity and Scalability A reliable partner should be able to grow with your business. Evaluate their production capacity to ensure they can handle high-volume orders without compromising lead times. Strategic manufacturing clusters in states like Gujarat and Telangana often provide better logistical support and supply chain resilience. 4. Technical and R&D Support The best Montelukast Sodium API manufacturer do not just supply a product; they provide a partnership. This includes: Stability Data: Comprehensive data under various climatic conditions (Zone IVb). Technical Documentation: Support with regulatory queries and formulation challenges. Customization: Ability to provide specific grades (IP, BP, USP, EP) tailored to your market needs. Why India is the Preferred Sourcing Destination India accounts for a significant portion of the global API supply for several reasons: Feature Benefit for Buyers Cost-Effectiveness Lower manufacturing costs compared to Western markets without sacrificing quality. Advanced Infrastructure State-of-the-art R&D centers and automated manufacturing units. Global Export Expertise Indian manufacturers are well-versed in the regulatory requirements of over 200 countries. Skilled Workforce Access to a vast pool of chemists and regulatory experts. Checklist for Final Selection Before finalizing your contract with a Montelukast Sodium API supplier, use this checklist: Does the manufacturer have a proven track record with Montelukast Sodium? Are they willing to provide samples for lab-scale testing? Do they have valid DMF/CEP documentation for your target markets? Can they provide a transparent timeline for delivery and logistics? Is their facility open to third-party or customer audits? Conclusion: Partnering for Excellence Choosing the right Montelukast Sodium API manufacturer in India is a strategic decision that impacts your product's market reputation and patient safety. Leading manufacturers like Chemox Pharma set the industry benchmark by combining rigorous quality control with robust regulatory support. By focusing on compliance, purity, and scalability, you can secure a supply chain that not only meets today’s requirements but also supports your future growth in the global respiratory care market.
- [How API Manufacturers Collaborate with Pharma R&D Teams](https://chemoxpharma.com/how-api-manufacturers-collaborate-with-pharma-rd-teams/): In the complex landscape of modern medicine, the journey from a laboratory concept to a life-saving treatment is fraught with challenges. At the heart of this journey lies the Active Pharmaceutical Ingredient (API)—the chemical backbone of any drug. Traditionally, pharmaceutical companies and API manufacturers operated in silos, but the industry is witnessing a paradigm shift. Today, API manufacturer and Pharma R&D collaboration is no longer just a strategic advantage; it is a necessity for survival in an increasingly competitive market. Bridging the Gap: The Evolution of Collaboration The relationship between API manufacturers and pharmaceutical Research and Development (R&D) teams has evolved from a simple transactional vendor-client model to a deeply integrated partnership. This synergy is driven by the need for faster development timelines, cost efficiency, and higher quality standards. By engaging early in the drug development lifecycle, both parties can mitigate risks and ensure that the transition from small-scale synthesis to commercial production is seamless. 1. Early-Stage Engagement and Molecule Design Collaboration often begins during the discovery phase. Pharma R&D teams focus on therapeutic efficacy, while API manufacturers bring expertise in chemical synthesis and scalability. By working together at this stage, they can: Identify potential manufacturing hurdles early. Optimize the chemical route for cost and safety. Ensure that the molecule is "manufacturable" at a commercial scale. 2. Process Development and Scale-Up One of the most critical points of collaboration is the scale-up process. Moving a molecule from a few grams in a lab to metric tons in a factory requires sophisticated engineering. API manufacturers provide the technical infrastructure and process chemistry expertise to refine production methods, ensuring consistency and yield. 3. Quality by Design (QbD) and Regulatory Compliance Regulatory bodies like the FDA and EMA demand rigorous documentation and adherence to Current Good Manufacturing Practices (cGMP). Collaboration ensures that quality is built into the process from day one. Joint teams work on: Impurity Profiling: Identifying and controlling potential impurities. Analytical Method Development: Creating robust testing protocols. Regulatory Documentation: Preparing the Chemistry, Manufacturing, and Controls (CMC) section of regulatory filings. Key Benefits of Integrated Collaboration The following table summarizes the primary advantages of a strong partnership between API manufacturers and Pharma R&D teams: Benefit Description Accelerated Time-to-Market Streamlined technology transfers and early risk mitigation shorten the development cycle. Cost Optimization Efficient process design reduces waste and lowers the overall cost of production. Risk Mitigation Early identification of stability or scalability issues prevents costly late-stage failures. Regulatory Success Higher quality documentation and process control lead to smoother approval processes. Supply Chain Resilience Integrated partnerships foster better communication, ensuring a stable supply of critical ingredients. The Rise of the CDMO Model The trend toward collaboration has led to the rise of Contract Development and Manufacturing Organizations (CDMOs). These entities offer an end-to-end solution, combining R&D capabilities with large-scale manufacturing. For many pharmaceutical companies, especially virtual or mid-sized firms, partnering with a CDMO provides access to world-class expertise without the need for massive capital investment in infrastructure. Future Trends: Digitalization and Sustainability As we look toward the future, two major trends are reshaping collaboration: Digitalization: The use of AI and machine learning to predict chemical reactions and optimize manufacturing processes in real-time. Green Chemistry: A shared commitment to sustainable manufacturing practices, reducing the environmental footprint of API production. Conclusion The collaboration between API manufacturers and Pharma R&D teams is the engine driving pharmaceutical innovation. By breaking down silos and fostering a culture of transparency and shared goals, the industry can deliver safer, more effective, and more affordable medicines to patients worldwide. As drug molecules become increasingly complex, the strength of these partnerships will define the next generation of healthcare breakthroughs.

## Pages
- [Export Inquiry](https://chemoxpharma.com/export-inquiry/): Global Export Inquiry Partner with a trusted pharmaceutical API exporter delivering high-quality products with complete regulatory and logistics support. Our team assists distributors, manufacturers, and healthcare companies worldwide with reliable supply solutions. ✔ GMP & international quality standards ✔ Fast quotation and response support ✔ Worldwide shipping assistance ✔ COA, MSDS & export documentation support ✔ Bulk manufacturing & long-term supply capabilities Full Name: Email: Phone No.: Country: Products: API ProductsIntermediate Products Message:
- [API Exporter to Uruguay](https://chemoxpharma.com/api-exporter-uruguay/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Peru](https://chemoxpharma.com/api-exporter-peru/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Paraguay](https://chemoxpharma.com/api-exporter-paraguay/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Ecuador](https://chemoxpharma.com/api-exporter-ecuador/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Costa Rica](https://chemoxpharma.com/api-exporter-costa-rica/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Chile](https://chemoxpharma.com/api-exporter-chile/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Argentina](https://chemoxpharma.com/api-exporter-argentina/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [Privacy Policy](https://chemoxpharma.com/privacy-policy/): Our website address is: https://chemoxpharma.com.
- [API Exporter to Jordan](https://chemoxpharma.com/api-exporter-jordan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Azerbaijan](https://chemoxpharma.com/api-exporter-azerbaijan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Moldova](https://chemoxpharma.com/api-exporter-moldova/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Armenia](https://chemoxpharma.com/api-exporter-armenia/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Turkmenistan](https://chemoxpharma.com/api-exporter-turkmenistan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Tajikistan](https://chemoxpharma.com/api-exporter-tajikistan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Kyrgyzstan](https://chemoxpharma.com/api-exporter-kyrgyzstan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Kazakhstan](https://chemoxpharma.com/api-exporter-kazakhstan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Agra](https://chemoxpharma.com/api-manufacturer-agra/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Delhi](https://chemoxpharma.com/api-manufacturer-delhi/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Kolkata](https://chemoxpharma.com/api-manufacturer-kolkata/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Chandigarh](https://chemoxpharma.com/api-manufacturer-chandigarh/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Baddi](https://chemoxpharma.com/api-manufacturer-baddi/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Solan](https://chemoxpharma.com/api-manufacturer-solan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Roorkee](https://chemoxpharma.com/api-manufacturer-roorkee/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Bangalore](https://chemoxpharma.com/api-manufacturer-bangalore/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Pune](https://chemoxpharma.com/api-manufacturer-pune/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Hyderabad](https://chemoxpharma.com/api-manufacturer-hyderabad/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [Other Events](https://chemoxpharma.com/other-events/)
- [API Exporter to Mexico](https://chemoxpharma.com/api-exporter-mexico/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Myanmar](https://chemoxpharma.com/api-exporter-myanmar/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Vadodara](https://chemoxpharma.com/api-manufacturer-vadodara/): In the rapidly evolving landscape of global medicine, the demand for high-quality Active Pharmaceutical Ingredients (APIs) has never been greater. Chemox Pharma stands at the forefront of this industry as a leading API Manufacturer in Vadodara. Our presence in Vadodara is not just about geographical proximity; it's about being strategically positioned to fuel the pharmaceutical clusters that drive innovation for patients worldwide.
- [Global Presence](https://chemoxpharma.com/global-presence/): Partnering with pharmaceutical leaders across regions to deliver high-purity APIs and specialized chemical synthesis solutions.
- [API Exporter to Belarus](https://chemoxpharma.com/api-exporter-belarus/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Uzbekistan](https://chemoxpharma.com/api-exporter-uzbekistan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Colombia](https://chemoxpharma.com/api-exporter-colombia/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Brazil](https://chemoxpharma.com/api-exporter-brazil/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Russia](https://chemoxpharma.com/api-exporter-russia/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Nigeria](https://chemoxpharma.com/api-exporter-nigeria/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Pakistan](https://chemoxpharma.com/api-exporter-pakistan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Egypt](https://chemoxpharma.com/api-exporter-egypt/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to South Korea](https://chemoxpharma.com/api-exporter-south-korea/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Japan](https://chemoxpharma.com/api-exporter-japan/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Indonesia](https://chemoxpharma.com/api-exporter-indonesia/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Thailand](https://chemoxpharma.com/api-exporter-thailand/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Vietnam](https://chemoxpharma.com/api-exporter-vietnam/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to Bangladesh](https://chemoxpharma.com/api-exporter-bangladesh/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Partner in UAE](https://chemoxpharma.com/api-partner-uae/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Exporter to USA](https://chemoxpharma.com/api-exporter-usa/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Manufacturer in Mumbai](https://chemoxpharma.com/api-manufacturer-mumbai/): Empowering Global Healthcare with High-Purity Active Pharmaceutical Ingredients and Advanced Chemical Solutions.
- [API Supplier in Ahmedabad](https://chemoxpharma.com/api-manufacturer-ahmedabad/): In the rapidly evolving landscape of global medicine, the demand for high-quality Active Pharmaceutical Ingredients (APIs) has never been greater. Chemox Pharma stands at the forefront of this industry as a leading API Supplier in Ahmedabad. Our presence in Ahmedabad is not just about geographical proximity; it's about being strategically positioned to fuel the pharmaceutical clusters that drive innovation for patients worldwide.

## Products
- [Loumstine](https://chemoxpharma.com/products/loumstine/): Product Name: Lomustine Grade: USP/EP Therapeutic Category: Anti-Neoplastic (Anti-Cancer) CAS Number: 13010-47-4 IH-DMF: N/A Molecular Formula: C₉H₁₆ClN₃O₂ Molecular Weight: 233.70 g/mol Appearance: Yellow to pale yellow crystalline powder Solubility: Soluble in alcohol and organic solvents; slightly soluble in water Storage: Store in a cool, dry place in tightly closed containers, protected from light and moisture. Shelf Life: As per the manufacturer's Certificate of Analysis (CoA).
- [Deferoxamine Mesylate](https://chemoxpharma.com/products/deferoxamine-mesylate/): Chemox Pharma is a leading and a top Deferoxamine Mesylate manufacturer in India, supplying high-quality pharmaceutical-grade APIs to global markets. Deferoxamine Mesylate is a potent iron-chelating agent widely used in the treatment of acute iron poisoning and chronic iron overload disorders.
- [Benfotiamine](https://chemoxpharma.com/products/benfotiamine/): Chemical Name: Benfotiamine (S-benzoylthiamine O-monophosphate) CAS Number: 22457-89-2 Molecular Formula: C₁₉H₂₃N₄O₆PS Molecular Weight: 466.45 g/mol Therapeutic Uses: Diabetic neuropathy, neuroprotection, nerve & vascular health Specifications: IH  Appearance: White to off-white crystalline powder Storage: Cool, dry area below 25°C, tightly sealed Therapeutic Class: Diabetic Polyneuropathy | Vitamin B1 analogue | Neuroprotective | Antioxidant | Lipid-soluble derivative
- [Ethyl 4-(2-hydroxy-2-propyl)-2-propyl-imidazole-5-carboxylate (CAS 144689-93-0)](https://chemoxpharma.com/products/olmesartan/): API Name / End Use: Olmesartan (Intermediate – OLMI-1)
- [4-(Chloromethyl)-5-methyl-1,3-dioxol-2-one (CAS 80841-78-7)](https://chemoxpharma.com/products/4-chloromethyl-5-methyl-13-dioxol-2-one-cas-80841-78-7/): API Name / End Use: Olmesartan (Intermediate – DMDO-CL)
- [8-Bromo-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione (CAS 853029-57-9)](https://chemoxpharma.com/products/8-bromo-7-but-2-ynyl-3-methyl-1-4-methylquinazolin-2-ylmethylpurine-26-dione-cas-853029-57-9/): API Name / End Use: Linagliptin (Intermediate – BBQ)
- [(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-[4-chloro-3-(4-ethoxybenzyl)phenyl]tetrahydro-2H-pyran-3,4,5-triyl triacetatee (CAS 461432-25-2-7)](https://chemoxpharma.com/products/2r3r4r5s6s-2-acetoxymethyl-6-4-chloro-3-4-ethoxybenzylphenyltetrahydro-2h-pyran-345-triyl-triacetatee-cas-461432-25-2-7/): API Name / End Use: Dapagliflozin (Intermediate)
- [5-Bromo-2-chloro-4’-ethoxydiphenylmethane (CAS 461432-23-5)](https://chemoxpharma.com/products/5-bromo-2-chloro-4-ethoxydiphenylmethane-cas-461432-23-5/): CAS Number: 461432-23-5
- [Montelukast Sodium](https://chemoxpharma.com/products/montelukast-sodium/): Chemical Name: 1-(((R)-3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-propyl)thiourea sodium salt
- [Pantoprazole](https://chemoxpharma.com/products/pantoprazole/): Chemical Name: Pantoprazole
- [Rosuvastatin Calcium](https://chemoxpharma.com/products/rosuvastatin-calcium/): Chemical Name: Rosuvastatin Calcium
- [Deflazacort](https://chemoxpharma.com/products/deflazacort/): Chemical Name: Deflazacort
- [Azithromycin](https://chemoxpharma.com/products/azithromycin/): Chemical Name : Azithromycin
- [5-(4′-(Bromomethyl)-[1,1′-biphenyl]-2-yl)-1-trityl-1H-tetrazole (TTBB) (CAS 124750-51-2)](https://chemoxpharma.com/products/cas-124750-51-2-sartan-family/): API name/end use: Sartan family Cas number: 124750-51-2 Molecular formula: C33H25BrN4 Molecular Weight: 557.48 Appearance: Solid Powder Storage: Room Temperature (Recommended in a cool and dark place, <15°C)
- [D-Tryptophan Methyl Ester Hydrochloride (CAS 14907-27-8)](https://chemoxpharma.com/products/cas-14907-27-8-tadalafil-intermediate/): API name/end use: Tadalafil Cas number: 14907-27-8 Molecular formula: C12H14N2O2·HCl Molecular Weight: 254.71 Appearance: Solid Powder Storage: Room Temperature (Recommended in a cool and dark place, <15°C)
- [(alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol (CAS 223673-34-5)](https://chemoxpharma.com/products/cas-223673-34-5-mirabegron-intermediate/): API name/end use: Mirabegron Cas number: 223673-34-5 Molecular formula: C16H18N2O3 Molecular Weight: 286.33 Appearance: Solid crystalline powder Storage: 2-8°C Refrigerator
- [(alphaR)-alpha-[[[2-(4-Aminophenyl)ethyl]amino]methyl]benzenemethanol hydrochloride (CAS 521284-22-0)](https://chemoxpharma.com/products/cas-521284-22-0-mirabegron-intermediate/): API name/end use: Mirabegron Cas number: 521284-22-0 Molecular formula: C16H21ClN2O Molecular Weight: 292.81 Appearance: Solid crystalline powder Storage: Keep in dark place, Inert atmosphere, Room temperature
- [8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione (CAS 666816-98-4)](https://chemoxpharma.com/products/cas-666816-98-4-linagliptin-intermediate/): API name/end use: Linagliptin Cas number: 666816-98-4 Molecular formula: C10H9BrN4O2 Molecular Weight: 297.11 Appearance: White - Almost white Crystal Powder Storage: Room Temperature (Recommended in a cool and dark place, <15°C)
- [1-(3,4-Dimethoxyphenethyl) urea (CAS 25017-47-4)](https://chemoxpharma.com/products/cas-25017-47-4-ensifentrine-intermediate/): API name/end use: Ensifentrine Cas number: 25017-47-4 Molecular formula: C11H16N2O3 Molecular Weight: 224.26 Appearance: White to Off-White Solid Powder Storage: Sealed in dry, Room Temperature
- [(3S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan (CAS 915095-94-2)](https://chemoxpharma.com/products/cas-915095-94-2-empagliflozin-intermediate/): API name/end use: Empagliflozin Cas number: 915095-94-2 Molecular formula: C17H16ClIO2 Molecular Weight: 414.67 Appearance: White to Off-White Solid powder Storage: 2-8°C Refrigerator
- [(3S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydro-furan (CAS 915095-89-5)](https://chemoxpharma.com/products/cas-915095-89-5-empagliflozin-intermediate/): API name/end use: Empagliflozin Cas number: 915095-89-5 Molecular formula: C17H16BrClO2 Molecular Weight: 367.66 Appearance: White to Off-White powder Storage: Sealed in dry, Room Temperature
- [2-[5-Bromo-2-methylphenyl) methyl]-5-(4-fluorophenyl) thiophene (CAS1030825-20-7)](https://chemoxpharma.com/products/cas-1030825-20-7-canagliflozin-intermediate/): Chemical Name: 2--5-(4-fluorophenyl)thiophene, 2--5-(4-fluorophenyl)thiophene API name/end use: Canagliflozin Cas number: 1030825-20-7 Molecular formula: C18H14BrFS Molecular Weight: 361.27 Appearance: White to Off-White Solid Storage: 2-8°C Refrigerator
- [3-(Dimethylamino)-1-(naphthalen-1-yl) propan-1-one hydrochloride (CAS 5409-58-5)](https://chemoxpharma.com/products/bedaquiline-intermediate/): API name/end use: Bedaquiline Cas number: 5409-58-5 Molecular formula: C15H18ClNO Molecular Weight: 263.76 Appearance: White to off-white powder Storage: Room Temperature
- [MIRABEGRON](https://chemoxpharma.com/products/mirabegron/): Chemical name: (R)-2-(2-Aminothiazol-4-yl)-N- ethyl] phenyl] acetamide, 2-Amino-N- amino] ethyl] phenyl]-4-thiazoleacetamide Cas number: 223673-61-8 Molecular formula: C21H24N4O2S Molecular weight: 396.51 Therapeutic uses: Beta-3 adrenergic agonist Specifications: IP/EP/IH Appearance: White to Off-White Solid Storage: Room temperature <25°C Class: β3-AR (β3 adrenergic receptor)
- [EMTRICITABINE](https://chemoxpharma.com/products/emtricitabine/): Chemical name: 4-Amino-5-fluoro-1--2-(1H-pyrimidinone) Cas number: 143491-57-0 Molecular formula: C8H10FN3O3S Molecular weight: 247.24 Therapeutic uses: Nucleoside transcriptase inhibitor Specifications: IP/BP/USP Appearance: White to Off-White Solid Storage: Room Temperature (Recommended in a cool and dark place, <15°C) Therapeutic Class: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- [DORZOLAMIDE](https://chemoxpharma.com/products/dorzolamide/): Chemical name: (4S,6S)-4-(Ethyl amino)-5,6-dihydro-6-methyl-4H-thieno thiopyran-2-sulfonamide 7,7-Dioxide Hydrochloride Cas number: 130693-82-2 Molecular formula: C10H16N2O4S3·HCl Molecular weight: 360.89 Therapeutic uses: Topical beta blockers Specifications: IP/BP/USP Appearance: White Solid Storage: Room temperature <25°C Therapeutic Class: TRC, Additional pharmaceutical toxicology reference materials
- [TIGECYCLINE](https://chemoxpharma.com/products/tigecycline/): Chemical name: 9-tert-Butylglycylamidominocycline (4S,4aS,5aR,12aS)-9-(2-(tert-Butyl amino) acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide Cas number: 220620-09-7 Molecular formula: C29H39N5O8 Molecular weight: 585.66 Therapeutic uses: Antibiotic, Antibacterial Specifications: IP/BP/USP Appearance: Orange solid Storage: Keep in dark place, inert atmosphere, store in freezer between 2-8°C Therapeutic Class: Glycylcycline antibiotic / Antibacterial
- [TADALAFIL CITRATE](https://chemoxpharma.com/products/tadalafil-api-manufacturer/): Chemical name: (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo heptadeca-1(10),11,13,15-tetraene-4,7-dione Cas number: 171596-29-5 Molecular formula: C22H19N3O4 Molecular weight: 389.41 g/mol Therapeutic uses: Erectile Dysfunction Specifications: IP/BP/EP/USP Appearance: White crystal powder Development status: Commercial Storage: Room temperature <25°C Therapeutic Class: Phosphodiesterase 5 inhibitor (PDE5)
- [SILDENAFIL CITRATE](https://chemoxpharma.com/products/sildenafil-citrate/): Chemical name: Sildenafil citrate salt, 1- pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate salt Cas number: 171599-83-0 Molecular formula: C22H30N6O4S·C6H8O7 Molecular weight: 666.70 Therapeutic uses: Erectile Dysfunction Specifications: IP/EP/USP Appearance: White hydroscopic crystalline powder Storage: Room Temperature in a cool and dark place, <25°C Therapeutic Class: PDE5 inhibitor
- [NITROFURANTOIN](https://chemoxpharma.com/products/nitrofurantoin/): Chemical name: 1-hydantoin, 1-amino]-2,4-imidazolidinedione Cas number: 67-20-9 Molecular formula: C8H6N4O5 Molecular weight: 238.16 Therapeutic uses: Antibiotic, Antibacterial Specifications: IP/BP/USP Appearance: Pale Yellow Crystalline Powder Storage: Room Temperature (Recommended in a cool and dark place, <25°C) Therapeutic Class: Nitrofuran derivative
- [FLUCONAZOLE](https://chemoxpharma.com/products/fluconazole/): Chemical name: 2-(2,4-Difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl) propan-2-ol, α-(2,4-Difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazol-1-ethanol Cas number: 86386-73-4 Molecular formula: C13H12F2N6O Molecular weight: 306.27 Therapeutic uses: Anti – Fungal / Triazoles Specifications: IP/BP/USP Appearance: White or almost white crystalline powder Storage: Keep in dark place, sealed in dry, room temperature <25°C Therapeutic Class: Intermediates, heterocycles, aromatics, Fine Chemicals
- [FEXOFENADINE HYDROCHLORIDE](https://chemoxpharma.com/products/fexofenadine-hydrochloride/): Chemical name: (±)-2-butyl]phenyl]-2-methylpropanoic acid. Cas number: 153439-40-8 Molecular formula: C32H39NO4 · HCl Molecular weight: 538.12 Therapeutic uses: Antihistamines Specifications: IP/BP/USP Appearance: White to Almost white crystal powder Storage: Room temperature < 25°C Therapeutic Class: Anti-histamine API
- [FENOFIBRATE](https://chemoxpharma.com/products/fenofibrate/): Chemical name: Isopropyl 2-(4-(4-chlorobenzoyl) phenoxy)-2-methylpropanoate, Procetofen, Lipofene, 2--2-methyl-propanoic acid 1-methylethyl ester Cas number: 49562-28-9 Molecular formula: C20H21ClO4 Molecular weight: 360.83 Therapeutic uses: Anti-Cholesterol Specifications: IP/BP/USP Appearance: White to off-white crystalline powder Storage: Room temperature <25°C Therapeutic Class: Lipid-lowering agent, heart disease prevention
- [CITICOLINE SODIUM](https://chemoxpharma.com/products/citicoline-sodium/): Chemical name: Acticolin. Cytidine-5'-diphosphocholine Sodium, sodium salt / 5'-O-phosphinato}oxy) phosphinato] cytidine de sodium or Citidine 5'-Diphosphocholine Sodium Cas number: 33818-15-4 Molecular formula: C14H25N4NaO11P2 Molecular weight: 510.31 Therapeutic uses: Nootropic, Psychostimulants Specifications: IH/IP/USP Appearance: White to off-white powder Storage: Room temperature <25°C, tightly sealed dry area. Therapeutic Class: Nootropic Agent | Neuroprotective Compound | CNS Stimulant (non-habit forming) | Phosphatidylcholine Precursor
- [ATORVASTATIN CALCIUM](https://chemoxpharma.com/products/atorvastatin-calcium/): Chemical name: Calcium (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate Cas number: 344423-98-9 Molecular formula: C66H68CaF2N4O10 Molecular Weight: 1155.3 g/mol Therapeutic uses: Anti-cholesterol Specifications: IP/BP/USP Appearance: White solid Storage: Room temperature (<25°C) Class: Synthetic lipid-lowering agent | HMG-CoA reductase inhibitor

## Product Categories
- [API](https://chemoxpharma.com/product-category/api/)
- [Intermediate](https://chemoxpharma.com/product-category/intermediate/)